Amgen Releases 8th Edition of Biosimilar Trends Report

Share on Social Media

Report Finds That Competition Created by Biosimilars Delivered $9.8 Billion in Savings Over the Past Five Years to the U.S. Healthcare System, Generating Savings for Patients, Payers and Employers
With Both a Strong Innovator Portfolio and a Deep Investment in Biosimilar Products, Amgen has Been a Pioneer in Biotechnology for ~40 Years and Invested Close to $2 Billion Across a Portfolio of 10 Biosimilar Medicines

THOUSAND OAKS, Calif., Sept. 22, 2021 /PRNewswire/ — Amgen (NASDAQ: AMGN) today released the 8th edition of the Biosimilar Trends Report, which examines the current state of the U.S. biosimilars marketplace across inflammation, oncology and nephrology categories, while a new feature considers how advancements in biosimilars can support the long-term success and sustainability of the U.S. healthcare system. To access the full report, visit: www.amgenbiosimilars.com/commitment/trends-report.

To view the multimedia assets associated with this release, please click: https://www.multivu.com/players/English/8812854-amgen-8th-edition-biosimilar-trends-report/  

The Report shows that competition created by biosimilars has saved the U.S. healthcare system $9.8 billion over the past five years,i and has the potential to reduce out-of-pocket spending by $238 million for patients in the nine biologic drug classes where biosimilars have been approved. According to the Report:

  • Biosimilars contribute to competition that drives down healthcare costs by providing significant wholesale acquisition cost (WAC) and average sales price (ASP) discounts at launch, resulting in additional savings over time.
  • Biosimilars are launching at a price that is generally 15% to 37% lower than the reference product.ii Furthermore, the ASP is declining for both reference products and biosimilars over time, while the rate of biosimilar uptake is generally increasing over time.iii,iv
  • Biosimilars have gained substantial share in the majority of therapeutic areas where they have been introduced.v For therapeutic areas with biosimilars launched in the last two years, the average share was 65%.vi

This year’s Report features a new section, Future State of the Marketplace, which outlines how biosimilars can continue to offer more affordable treatment options, drive cost savings through increased competition between biosimilars and with reference biologics, and promote a more resilient U.S. healthcare marketplace. The U.S. marketplace is poised to see further growth in biosimilars approved to date and welcome many new biosimilars in the years to come.

“As part of Amgen’s commitment to staying at the forefront of biosimilar education, Amgen is pleased to announce the launch of the 2021 Biosimilar Trends Report,” said Jennifer Norton, vice president, Head of U.S. Value and Access at Amgen. “The increasing availability and adoption of biosimilars means these treatments are delivering on the fundamental promise of reducing healthcare costs for payers, employers, and patients in the United States.”

The 2021 Biosimilar Trends Report also outlines the four key elements that Amgen believes are necessary for sustaining biosimilars’ growth:

  • Implementing scientifically appropriate regulatory standards for the approval, manufacture, and uninterrupted availability of safe and effective biological products, including biosimilars;
  • Maintaining a marketplace that encourages competition on a level playing field to achieve meaningful savings and long-term stability;
  • Providing scientifically accurate educational outreach to drive confidence with healthcare providers, patients, payers, and employers; and
  • Ensuring a foundation of strong intellectual property to encourage innovation and investment.

“The U.S. marketplace with biosimilars is well established and accelerating across key therapeutic areas, creating cost savings, and additional treatment options for physicians and patients,” said Chad Pettit, executive director, Marketing, Global Biosimilars Commercial Lead at Amgen, adding, “By continuing to advance science-based policies that support competition and enhance confidence from patients, physicians, and other stakeholders, the U.S. can help promote a robust and resilient healthcare system needed for the long term.”

About Amgen Biosimilars
Amgen is committed to building upon Amgen’s experience in the development and manufacturing of innovative human therapeutics to expand Amgen’s reach to patients with serious illnesses. Biosimilars help to maintain Amgen’s commitment to connect patients with vital medicines, and Amgen is well positioned to leverage its nearly four decades of experience in biotechnology to create high-quality biosimilars and reliably supply them to patients worldwide.

For more information, visit www.amgenbiosimilars.com and follow us on www.twitter.com/amgenbiosim.

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.  

CONTACT: Amgen, Thousand Oaks 
Megan Fox, 805-447-1423 (media)
Trish Rowland, 805-447-5631(media) 
Arvind Sood, 805-447-1060 (investors) 

Latest News

Mass Challenge Now Accepting Applications

Mass Challenge Now Accepting Applications

Launched in 2018, MassChallenge Rhode Island connects entrepreneurs to a powerful community of resources and support in Rhode Island and regional opportunities in Boston, in addition to our global network of leading corporate partners, policymakers, and innovation...

Welcome to a New Chapter, Welcome to RI Bio

Welcome to a New Chapter, Welcome to RI Bio

As we transition into 2019, MedMates is making a transition of its own.  After five years of many significant accomplishments and dedicated partnerships, MedMates will be transitioning into Rhode Island's only BIO affiliate, RI Bio. As part of our transition, you will...

A Letter from MedMates’ Executive Director to Culminate 2018

December 20, 2018 MedMates Colleagues and Friends: It has been a great year of growth and transformation for Rhode Island’s Life Sciences community.  I am very excited about the future of Life Sciences in our state and MedMates’ success as a growing vibrant hub to...

Biotech Industry News